Skip to main content
NCBI home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 2002 Feb;52(475):168–169.

Selling drugs to doctors--it's marketing, not education.

Richelle Cooper 1, Jerome Hoffman 1
PMCID: PMC1314227  PMID: 11885830

Full Text

The Full Text of this article is available as a PDF (93.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angell M. The pharmaceutical industry--to whom is it accountable? N Engl J Med. 2000 Jun 22;342(25):1902–1904. doi: 10.1056/NEJM200006223422509. [DOI] [PubMed] [Google Scholar]
  2. Avorn J., Chen M., Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982 Jul;73(1):4–8. doi: 10.1016/0002-9343(82)90911-1. [DOI] [PubMed] [Google Scholar]
  3. Beary J. F., 3rd Pharmaceutical marketing has real and proven value. Characteristics of materials distributed by drug companies: four points of view. J Gen Intern Med. 1996 Oct;11(10):635–636. doi: 10.1007/BF02599032. [DOI] [PubMed] [Google Scholar]
  4. Ferner R. E., Scott D. K. Whatalotwegot--the messages in drug advertisements. BMJ. 1994 Dec 24;309(6970):1734–1736. doi: 10.1136/bmj.309.6970.1734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Findlay S. D. Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers. Pharmacoeconomics. 2001;19(2):109–119. doi: 10.2165/00019053-200119020-00001. [DOI] [PubMed] [Google Scholar]
  6. Frey John. Selling drugs to the public--should the UK follow the example of the US? Br J Gen Pract. 2002 Feb;52(475):170–171. [PMC free article] [PubMed] [Google Scholar]
  7. Frieden T. R., Mangi R. J. Inappropriate use of oral ciprofloxacin. JAMA. 1990 Sep 19;264(11):1438–1440. [PubMed] [Google Scholar]
  8. Goodman B. Do drug company promotions influence physician behavior? West J Med. 2001 Apr;174(4):232–233. doi: 10.1136/ewjm.174.4.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Griffith D. Reasons for not seeing drug representatives. BMJ. 1999 Jul 10;319(7202):69–70. doi: 10.1136/bmj.319.7202.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gutknecht D. R. Evidence-based advertising? A survey of four major journals. J Am Board Fam Pract. 2001 May-Jun;14(3):197–200. [PubMed] [Google Scholar]
  11. Herxheimer A., Collier J. Promotion by the British pharmaceutical industry, 1983-8: a critical analysis of self regulation. BMJ. 1990 Feb 3;300(6720):307–311. doi: 10.1136/bmj.300.6720.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet. 2001 May 19;357(9268):1544–1545. doi: 10.1016/S0140-6736(00)04776-0. [DOI] [PubMed] [Google Scholar]
  13. Kessler D. A. Addressing the problem of misleading advertising. Ann Intern Med. 1992 Jun 1;116(11):950–951. doi: 10.7326/0003-4819-116-11-950. [DOI] [PubMed] [Google Scholar]
  14. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ. 1993 Nov 15;149(10):1401–1407. [PMC free article] [PubMed] [Google Scholar]
  16. Rothermich E. A., Pathak D. S., Smeenk D. A. Health-related quality-of-life claims in prescription drug advertisements. Am J Health Syst Pharm. 1996 Jul 1;53(13):1565–1569. doi: 10.1093/ajhp/53.13.1565. [DOI] [PubMed] [Google Scholar]
  17. Shapiro M. F. Regulating pharmaceutical advertising: what will work? CMAJ. 1997 Feb 1;156(3):359–361. [PMC free article] [PubMed] [Google Scholar]
  18. Stryer D., Bero L. A. Characteristics of materials distributed by drug companies. An evaluation of appropriateness. J Gen Intern Med. 1996 Oct;11(10):575–583. doi: 10.1007/BF02599024. [DOI] [PubMed] [Google Scholar]
  19. Temple R., O'Brien P. Why would anyone have expected anything else? Characteristics of materials distributed by drug companies: four points of view. J Gen Intern Med. 1996 Oct;11(10):640–641. doi: 10.1007/BF02599034. [DOI] [PubMed] [Google Scholar]
  20. Wang T. J., Ausiello J. C., Stafford R. S. Trends in antihypertensive drug advertising, 1985-1996. Circulation. 1999 Apr 20;99(15):2055–2057. doi: 10.1161/01.cir.99.15.2055. [DOI] [PubMed] [Google Scholar]
  21. Waud D. R. Pharmaceutical promotions--a free lunch? N Engl J Med. 1992 Jul 30;327(5):351–353. doi: 10.1056/NEJM199207303270511. [DOI] [PubMed] [Google Scholar]
  22. Wilkes M. S., Doblin B. H., Shapiro M. F. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med. 1992 Jun 1;116(11):912–919. doi: 10.7326/0003-4819-116-11-912. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES